271 related articles for article (PubMed ID: 34890975)
1. Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures.
Hu M; Lei XY; Larson JD; McAlonis M; Ford K; McDonald D; Mach K; Rusert JM; Wechsler-Reya RJ; Mali P
Biomaterials; 2022 Jan; 280():121276. PubMed ID: 34890975
[TBL] [Abstract][Full Text] [Related]
2. A CRISPR Platform for Targeted In Vivo Screens.
Maranda V; Zhang Y; Vizeacoumar FS; Freywald A; Vizeacoumar FJ
Methods Mol Biol; 2023; 2614():397-409. PubMed ID: 36587138
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.
Munoz DM; Cassiani PJ; Li L; Billy E; Korn JM; Jones MD; Golji J; Ruddy DA; Yu K; McAllister G; DeWeck A; Abramowski D; Wan J; Shirley MD; Neshat SY; Rakiec D; de Beaumont R; Weber O; Kauffmann A; McDonald ER; Keen N; Hofmann F; Sellers WR; Schmelzle T; Stegmeier F; Schlabach MR
Cancer Discov; 2016 Aug; 6(8):900-13. PubMed ID: 27260157
[TBL] [Abstract][Full Text] [Related]
4. Genome-scale CRISPR pooled screens.
Sanjana NE
Anal Biochem; 2017 Sep; 532():95-99. PubMed ID: 27261176
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
Xue VW; Wong SCC; Cho WCS
Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 for cancer research and therapy.
Zhan T; Rindtorff N; Betge J; Ebert MP; Boutros M
Semin Cancer Biol; 2019 Apr; 55():106-119. PubMed ID: 29673923
[TBL] [Abstract][Full Text] [Related]
7. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
8. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
[TBL] [Abstract][Full Text] [Related]
9. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
10. Guide RNA Design for Genome-Wide CRISPR Screens in Yarrowia lipolytica.
Ramesh A; Wheeldon I
Methods Mol Biol; 2021; 2307():123-137. PubMed ID: 33847986
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens.
Hart T; Tong AHY; Chan K; Van Leeuwen J; Seetharaman A; Aregger M; Chandrashekhar M; Hustedt N; Seth S; Noonan A; Habsid A; Sizova O; Nedyalkova L; Climie R; Tworzyanski L; Lawson K; Sartori MA; Alibeh S; Tieu D; Masud S; Mero P; Weiss A; Brown KR; Usaj M; Billmann M; Rahman M; Constanzo M; Myers CL; Andrews BJ; Boone C; Durocher D; Moffat J
G3 (Bethesda); 2017 Aug; 7(8):2719-2727. PubMed ID: 28655737
[TBL] [Abstract][Full Text] [Related]
12. CRISPR therapeutic tools for complex genetic disorders and cancer (Review).
Baliou S; Adamaki M; Kyriakopoulos AM; Spandidos DA; Panayiotidis M; Christodoulou I; Zoumpourlis V
Int J Oncol; 2018 Aug; 53(2):443-468. PubMed ID: 29901119
[TBL] [Abstract][Full Text] [Related]
13. Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening.
Sun N; Petiwala S; Wang R; Lu C; Hu M; Ghosh S; Hao Y; Miller CP; Chung N
BMC Genomics; 2019 Mar; 20(1):225. PubMed ID: 30890156
[TBL] [Abstract][Full Text] [Related]
14. Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
Guo X; Chitale P; Sanjana NE
Adv Exp Med Biol; 2017; 1016():123-145. PubMed ID: 29130157
[TBL] [Abstract][Full Text] [Related]
15. Reduced gene templates for supervised analysis of scale-limited CRISPR-Cas9 fitness screens.
Vinceti A; Perron U; Trastulla L; Iorio F
Cell Rep; 2022 Jul; 40(4):111145. PubMed ID: 35905712
[TBL] [Abstract][Full Text] [Related]
16. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
17. Multiplex enCas12a screens detect functional buffering among paralogs otherwise masked in monogenic Cas9 knockout screens.
Dede M; McLaughlin M; Kim E; Hart T
Genome Biol; 2020 Oct; 21(1):262. PubMed ID: 33059726
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
Li Y; Glass Z; Huang M; Chen ZY; Xu Q
Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
[TBL] [Abstract][Full Text] [Related]
19. iCSDB: an integrated database of CRISPR screens.
Choi A; Jang I; Han H; Kim MS; Choi J; Lee J; Cho SY; Jun Y; Lee C; Kim J; Lee B; Lee S
Nucleic Acids Res; 2021 Jan; 49(D1):D956-D961. PubMed ID: 33137185
[TBL] [Abstract][Full Text] [Related]
20. Guide RNA library-based CRISPR screens in plants: opportunities and challenges.
Pan C; Li G; Bandyopadhyay A; Qi Y
Curr Opin Biotechnol; 2023 Feb; 79():102883. PubMed ID: 36603502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
